Historical Valuation
Vera Therapeutics Inc (VERA) is now in the Fair zone, suggesting that its current forward PS ratio of 578.17 is considered Fairly compared with the five-year average of -7.83. The fair price of Vera Therapeutics Inc (VERA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：48.71
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vera Therapeutics Inc (VERA) has a current Price-to-Book (P/B) ratio of 7.79. Compared to its 3-year average P/B ratio of 5.69 , the current P/B ratio is approximately 36.91% higher. Relative to its 5-year average P/B ratio of 5.21, the current P/B ratio is about 49.49% higher. Vera Therapeutics Inc (VERA) has a Forward Free Cash Flow (FCF) yield of approximately -6.13%. Compared to its 3-year average FCF yield of -11.10%, the current FCF yield is approximately -44.79% lower. Relative to its 5-year average FCF yield of -10.42% , the current FCF yield is about -41.18% lower.
P/B
Median3y
5.69
Median5y
5.21
FCF Yield
Median3y
-11.10
Median5y
-10.42
Competitors Valuation Multiple
AI Analysis for VERA
The average P/S ratio for VERA competitors is 840.84, providing a benchmark for relative valuation. Vera Therapeutics Inc Corp (VERA.O) exhibits a P/S ratio of 578.17, which is -31.24% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VERA
1Y
3Y
5Y
Market capitalization of VERA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VERA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VERA currently overvalued or undervalued?
Vera Therapeutics Inc (VERA) is now in the Fair zone, suggesting that its current forward PS ratio of 578.17 is considered Fairly compared with the five-year average of -7.83. The fair price of Vera Therapeutics Inc (VERA) is between to according to relative valuation methord.
What is Vera Therapeutics Inc (VERA) fair value?
VERA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vera Therapeutics Inc (VERA) is between to according to relative valuation methord.
How does VERA's valuation metrics compare to the industry average?
The average P/S ratio for VERA's competitors is 840.84, providing a benchmark for relative valuation. Vera Therapeutics Inc Corp (VERA) exhibits a P/S ratio of 578.17, which is -31.24% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Vera Therapeutics Inc (VERA) as of Jan 10 2026?
As of Jan 10 2026, Vera Therapeutics Inc (VERA) has a P/B ratio of 7.79. This indicates that the market values VERA at 7.79 times its book value.
What is the current FCF Yield for Vera Therapeutics Inc (VERA) as of Jan 10 2026?
As of Jan 10 2026, Vera Therapeutics Inc (VERA) has a FCF Yield of -6.13%. This means that for every dollar of Vera Therapeutics Inc’s market capitalization, the company generates -6.13 cents in free cash flow.
What is the current Forward P/E ratio for Vera Therapeutics Inc (VERA) as of Jan 10 2026?
As of Jan 10 2026, Vera Therapeutics Inc (VERA) has a Forward P/E ratio of -9.50. This means the market is willing to pay $-9.50 for every dollar of Vera Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vera Therapeutics Inc (VERA) as of Jan 10 2026?
As of Jan 10 2026, Vera Therapeutics Inc (VERA) has a Forward P/S ratio of 578.17. This means the market is valuing VERA at $578.17 for every dollar of expected revenue over the next 12 months.